Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

HPV-related throat cancer cases increase sharply over the past 10 years

Forty-two-year-old Manahawkin, New Jersey resident David Caldarella can recite a long list of dates off the top of his head. The first one starts with the day he found a lump on the right side of his neck while shaving. It was March 23, 2010. Caldarella immediately called his physician.

8 Aug 2011

U.S. physicians spend more time, money for interaction with health plans than Canadian doctors

Physicians in the United States spend nearly four times as much dealing with health insurers and payers compared with doctors in Canada. Most of the difference stems from the fact that Canadian physicians deal with a single payer, in contrast to the multiple payers in the United States.

5 Aug 2011

Study finds HIV epidemics emerging in the Middle East and North Africa among gays

HIV epidemics are emerging in several countries in the Middle East and North Africa among men who have sex with men, a term that encompasses gay, non-gay identified homosexual men, and transgendered and bisexual men.

3 Aug 2011

New birth control guidelines in U.S.

Planned parenting groups are cheering while some religious organizations are unhappy with the move that would require health insurance companies to provide women free birth control, in keeping with new Obama administration guidelines. The Department of Health and Human Services call it “historic” and also say that insurance companies must provide women with other preventive services free of charge.

1 Aug 2011

Accuray to showcase CyberKnife, TomoTherapy systems at AAPM/COMP meeting

Accuray Incorporated, the premier radiation oncology company, announced today that it will showcase the CyberKnife Robotic Radiosurgery System and the TomoTherapy Radiation Therapy Treatment System in the company's booths at the 2011 Joint American Association of Physicists in Medicine (AAPM)/Canadian Organization of Medical Physicists (COMP) Meeting.

1 Aug 2011

One in four British women at risk of cancer

A cancer charity revealed figures that show that British women are nearly a fifth more likely to develop cancer at some point during their lives than their European counterparts. Most of it is blamed on lifestyle factors such as obesity and alcohol consumption.

31 Jul 2011

Skin cancer vaccine on the way: Cancer expert Prof Ian Frazer

In a major medical breakthrough, cancer expert Prof Ian Frazer is on the verge of developing a vaccine against skin cancer within a year. The former ‘Australian of the Year’ and creator of the world's first cervical cancer vaccine, Gardasil, has developed a world-first strategy to combat the insidious disease that affects two out of three Australians.

31 Jul 2011

New fluorescent tool can track mysterious workings of cellular RNAs

The ability to tag proteins with a green fluorescent light to watch how they behave inside cells so revolutionized the understanding of protein biology that it earned the scientific teams who developed the technique Nobel Prizes in 2008.

30 Jul 2011

Carcinogenesis is just another form of speciation, proposes new theory

Cancer patients may view their tumors as parasites taking over their bodies, but this is more than a metaphor for Peter Duesberg, a molecular and cell biology professor at the University of California, Berkeley.

27 Jul 2011

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

26 Jul 2011

Beta HPV prophylactic strategies may have a positive impact on prevention of NMSC

Non-melanoma skin cancer is the most common form of malignancy in adult Caucasian populations, with more than a million cases recorded each year in the USA alone.

21 Jul 2011

Promising results from phase I study of Genentech's GDC-0941 for advanced breast cancer

A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology.

21 Jul 2011

MDL announces HPV-16 Status reflex test

Medical Diagnostic Laboratories, L.L.C. (MDL) is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

20 Jul 2011

DNA vaccine developer Coridon in U.S. collaboration

DNA vaccine development company Coridon Pty Ltd. today announced that it has entered into a research collaboration agreement with The Ohio State University to progress its Epstein Barr Virus (EBV) project.

19 Jul 2011

Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN

Mayo Clinic has licensed patent rights from QIAGEN to enable Mayo Medical Laboratories to offer an M. tuberculosis complex speciation test. The test expands Mayo Medical Laboratories' current offering for tuberculosis testing, which already includes M. tuberculosis complex culture, molecular identification and drug susceptibility testing.

From QIAGEN Manchester Limited 19 Jul 2011

Roche signs agreement to acquire mtm laboratories

Ventana Medical Systems, Inc., a member of the Roche Group, announced today that Roche has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany.

From Roche Sequencing and Life Science 19 Jul 2011

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

15 Jul 2011

FDA asks Guided Therapeutics to provide additional information on LuViva PMA

Guided Therapeutics, Inc., developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that, after a series of meetings with the U.S. Food and Drug Administration (FDA), and after reviewing draft responses, the FDA has asked the company to provide additional information in the company's response to one remaining question.

15 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

Source BioScience receives NHS approval for automated cervical cancer screening technology

Source BioScience (LSE: SBS), the international diagnostics and genetic analysis business, is pleased to announce that the National Health Service Cancer Screening Programmes (“NHSCSP”) has approved the use of the BD FocalPoint “No Further Review” technology for cervical cancer screening in the UK. This is the only automated cervical screening technology which has been approved.

13 Jul 2011